NCT04378569

Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema

A Phase 1/2b, Multiple Dose and 12-Week, Parallel Group, Double Blind, Dose Ranging, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-252 Cream 0.1% and ARQ-252 Cream 0.3% in Subjects With Chronic Hand Eczema

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 230 (actual)
• Sponsor: Arcutis Biotherapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will assess the safety and efficacy of ARQ-252 cream in subjects with chronic hand eczema

Detailed description

This is a Phase 1/2b multiple dose, parallel group, double blind, vehicle-controlled study of the safety and efficacy of ARQ-252 cream in subjects with chronic hand eczema

Conditions

• Chronic Hand Eczema

Interventions

Type	Name	Description
DRUG	ARQ-252 cream 0.3%	ARQ-252 cream 0.3%
DRUG	ARQ-252 cream 0.1%	ARQ-252 cream 0.1%
DRUG	ARQ-252 Vehicle Cream	ARQ-252 Vehicle Cream

Timeline

• Start date: 2020-04-20
• Primary completion: 2021-02-24
• Completion: 2021-02-24
• First posted: 2020-05-07
• Last updated: 2024-04-05
• Results posted: 2024-04-05

Locations

37 sites across 3 countries: United States, Australia, Canada

Regulatory

• FDA-regulated drug study